For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Atomoxetine hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
PAD Profile : Atomoxetine hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Information on management of ADHD medication stock shortages
There are currently supply disruptions affecting various medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD).
A national patient safety alert has been issued and we have been liaising with colleagues both regionally and nationally about the ongoing situation. We have been advised that centrally they are looking at publishing further guidance but until this is published we have been working with colleagues from Surrey & Borders Partnership NHS Trust and the Local Pharmaceutical Committee to produce the pack below which provides useful information and clinical recommendations about how to manage these shortages.
Shared Care arrangements for children and adolescents with ADHD are in place with Surrey and Borders Partnership NHS Foundation Trust.
Guildford & Waverley, North West Surrey and Surrey Downs have agreed a Locally Commissioned Service (LCS) for practices entering into the shared care agreement with Surrey & Borders Partnership. The LCS supports the provision of an annual physical medication review by the GP (with an annual review by the specialist so that the patient continues to receive a 6-monthly review in accordance with the product license)
See below for a copy of the Shared care with LCS agreement
There is also a non-LCS shared care agreement for all non-LCS participating practices (see shared care agreement below)